2nd trial

The chart shows the growth of an initial investment of $10,000 in 2nd trial, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Feb 13, 2020, 2nd trial's average daily return is +0.07%, while the average monthly return is +1.40%. At this rate, an investment would double in approximately 4.2 years.

Historically, 71% of months were positive and 29% were negative. The best month was Feb 2021 with a return of +10.6%, while the worst month was Mar 2020 at -16.6%. The longest winning streak lasted 13 consecutive months, and the longest losing streak was 3 months.

On a daily basis, 2nd trial closed higher 56% of trading days. The best single day was Mar 17, 2020 with a return of +9.4%, while the worst single day was Mar 16, 2020 at -12.5%.

2nd trial has an annualized alpha of 7.72%, beta of 0.69, and R2 of 0.58 versus S&P 500 Index. Calculated based on daily prices since February 13, 2020.

• This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (60.51%) than losses (32.18%) - typical of diversified or defensive assets.
• This portfolio generated an annualized alpha of 7.72% versus S&P 500 Index - delivering returns beyond what market exposure alone would predict.
• Beta of 0.69 indicates this portfolio moves significantly less than S&P 500 Index - a genuinely defensive profile with reduced participation in both market rallies and downturns.

2nd trial has an expense ratio of 0.04%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

2nd trial ranks 83 for risk / return — in the top 83% of Portfolios on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk. Learn how to interpret the Sharpe ratio.

The current 2nd trial Sharpe ratio is 2.69 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.56 to 2.44, this portfolio's current Sharpe ratio is in the top 25%. This signifies superior risk-adjusted performance, meaning the portfolio is delivering strong returns for the level of risk taken compared to most others.

The chart below shows the rolling Sharpe ratio of 2nd trial compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

2nd trial provided a 1.50% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the 2nd trial. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 2nd trial was 34.53%, occurring on Mar 23, 2020. Recovery took 176 trading sessions.

The current 2nd trial drawdown is 0.73%.

The chart below shows the rolling one-month volatility.